Sven Karlsson, CFA, MBA, is co-founder, chief operating officer, and chief business officer of Platelet BioGenesis, the only company in the world manufacturing functional human platelets. At PBG, he has grown the company from one employee to 25, raised more than $20 million in venture capital and non-dilutive grants, and advanced the company’s scalable, cGMP-compliant platelet bioreactor. PBG is developing a platelet platform to create an entirely new class of therapeutics: designer platelets to treat cancer and other life-threatening diseases. The company plans to enter the clinic with its first product, donor-independent platelets for transfusion, in 2021. Earlier in his career, Karlsson held a variety of board-level and senior positions in the renewable energy field, helping a variety of green energy startups raise their first financing rounds, find their first customers, and scale to profitability. Karlsson started his career as a senior analyst for M&A and business development at JPMorgan and also held positions at a number of asset management firms.